Monotherapy Study of MP-513 in Patients With Type 2 Diabetes

Phase 3 Completed 203 enrolled Tanabe Pharma Corporation

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.

Timeline

Start: 2009-09
Primary completion: 2010-06
Completion: 2010-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Teneligliptin	Small molecule	20 mg	Oral

Monotherapy Study of MP-513 in Patients With Type 2 Diabetes

Summary

Timeline

Drugs

Indications